Related Experiment Video

Updated: Oct 13, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.9K

[Features of anticoagulant therapy of atrial fibrillation in combination with impaired renal function]

T N Novikova1

  • 1I.I. Mechnikov North-Western State Medical University, Saint Petersburg.

Kardiologiia
|November 12, 2021
PubMed

Insights

For patients with atrial fibrillation and chronic kidney disease, rivaroxaban offers a safer alternative to warfarin, showing a more favorable effect on kidney function and comprehensive protection against stroke.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) face a high stroke risk, complicating anticoagulant selection.
  • Warfarin has demonstrated detrimental effects on kidney function, necessitating alternative treatments for moderate CKD stages.
  • Direct oral anticoagulants (DOACs) are emerging as potential alternatives, with specific focus on their renal impact.

Purpose of the Study:

  • To review the role and safety of anticoagulant therapy in patients with AF and CKD.
  • To evaluate rivaroxaban as a potential alternative to warfarin in this patient population.
  • To assess the impact of anticoagulants on kidney function in patients with moderate CKD.

Main Methods:

  • Review of randomized controlled studies and real-world clinical practice data.
  • Comparative analysis of warfarin and rivaroxaban efficacy and safety profiles.
  • Examination of renal function outcomes in patients receiving different anticoagulants.

Main Results:

  • Rivaroxaban has been specifically studied for its efficacy and safety in moderate CKD (stage 3-4) patients with AF.
  • Clinical studies indicate a more favorable effect of rivaroxaban on kidney function compared to warfarin.
  • Rivaroxaban demonstrated comprehensive protection against stroke in patients with AF and CKD.

Conclusions:

  • Rivaroxaban presents a viable and potentially superior alternative to warfarin for anticoagulation in patients with AF and moderate CKD.
  • The drug offers a favorable safety profile concerning kidney function, alongside effective stroke prevention.
  • Comprehensive management of AF in CKD patients may be best achieved with rivaroxaban based on current evidence.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.6K
Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.8K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
193
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
190
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
57
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
20